temple slot
Arsenal crush Sporting in Champions League to extend revivalNoneIt's always a great time to invest in quality businesses that can prime your portfolio for long-term growth. It's important to be selective with the companies that you add to your portfolio and ensure that you only put cash into investments that align with your overall investment priorities, risk tolerance, and long-term goals. You should also only put cash to work that you can leave in your portfolio for a few years, not funds that you might soon need for bills or other financial obligations. On that note, if you're looking for top-notch growth stocks to buy right now and have $1,000 available to invest, here are two names to consider. 1. Eli Lilly Eli Lilly ( LLY -0.26% ) has been the darling of pharmaceutical stocks in the last 12 to 18 months, with shares rocketing upward as the popularity of its GLP-1 drugs has propelled revenue and earnings. Bear in mind, this is one of the oldest healthcare companies in the world, with a lineup of top-selling drugs across a range of disease categories that target everything from various cancers and cardiovascular ailments to endocrine disorders and neurological conditions. In the first nine months of 2024 alone, shares roared upward to the tune of about 62%. After the company reported its earnings for the third quarter of 2024, shares took a double-digit nosedive as investors responded negatively to a few key points, including a slight pullback in full-year guidance. The company also reported financial figures that were slightly below what Wall Street had expected. In terms of its full-year guidance, where Eli Lilly was targeting revenue for the 12-month period in the $45.4 billion to $46.6 billion range, the company is now projecting that it will deliver in the ballpark of $45.4 billion to $46 billion. Its Q3 revenue was around $800 million below what analysts had aimed for. That being said, a closer look is warranted, and the long-term outlook for this business is anything but dismal. Revenue in Q3 2024 rose 20% year over year to $11.4 billion. The company sold rights for its olanzapine portfolio in Q3, featuring products used to treat ailments such as schizophrenia and bipolar disorder. If you exclude revenue from this portfolio, Eli Lilly's top line actually jumped 42% on a year-over-year basis, which is a bit more than the 36% growth it reported in the second quarter. The company also reported net income of approximately $970 million in Q3. Tirzepatide, which is the main active ingredient in its top-selling drugs Mounjaro (for diabetes) and Zepbound (for weight loss), is being studied by Eli Lilly across multiple other disease areas. For example, positive phase 3 trial data from a 176-week study of tirzepatide demonstrated a 94% reduction in the risk of developing type 2 diabetes in adults with pre-diabetes who are obese or overweight. Another first-of-its-kind study initiated by Eli Lilly has been studying tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. In this phase 3 trial, tirzepatide reduced heart failure symptoms and physical limitations while lowering the risk of worsening heart failure events by 38%. Risk of hospitalization for heart failure was also reduced by 56% in trial patients taking tirzepatide. In short, the future revenue and profit opportunities from tirzepatide may be in the very early innings. In Q3, sales of Mounjaro rose more than 121% year over year to $3.1 billion, while Zepbound (which was just approved last November) raked in $1.3 billion in sales. This was despite negative effects for both drugs cited by Eli Lilly that were caused by inventory decreases in the wholesaler channel. Blockbuster cancer drug Verzenio generated $1.37 billion in sales in the quarter, up 32% from one year ago, while sales of autoimmune disease drug Taltz jumped 18% to $879.6 million. While investors appear to be particularly reactionary in the current environment, that can present an opportunity for those with a sufficient buy-and-hold horizon to take a slice of the action. While Eli Lilly doesn't trade at a cheap valuation by any means, its annual dividend of $5.20 and steady increase to its payout can augment total investor returns. Investors who want to become part-owner in a top healthcare business with a steady global footprint may be remiss to overlook this quality stock. 2. Monday.com Monday.com ( MNDY 3.02% ) is a low-code and no-code platform that helps organizations build the work management tools and software applications they need to ensure business operations run smoothly. The company derives its revenue from monthly or annual subscription agreements that it enters into with customers who use its cloud-based platform. Monday.com's software enables everything from project management and collaboration to helping keep tools and files in a single location for easy access. Clients with little to no coding experience can leverage its platform to develop customized workflow apps featuring boards, charts, and other important automation solutions. Companies like Canva, Lionsgate , and Coca-Cola are just a handful of the big names on Monday.com's client roster. Investors have been particularly optimistic about Monday.com's performance recently, with shares skyrocketing to the tune of about 50% over the trailing 12-month period. As always, share price is never a reason to buy (or sell) a stock. You need to look at the underlying business, its drivers and detractors of growth, its financial performance, its industry, and its long-term growth runway to gain a clear picture of whether it's a wise fit for your portfolio. In the case of Monday.com, the company has only been in business since 2012, so it's still in the relatively early stages of its potential growth story. Management estimates that the company operates in a large and growing total addressable market, which could hit a valuation of $150 billion by the year 2026. The diverse range of solutions that Monday.com's platform offers allows it to target various segments of its overall market opportunity, including the $30 billion customer relationship management (CRM) software market. From a financial perspective, Monday.com is doing quite well. Its third-quarter revenue rose 33% from the year-ago period to $251 million, and the company officially surpassed the $1 billion annual recurring revenue (ARR) mark. Its overall net dollar retention rate (NRR) increased to 111%, while NRR for customers with more than $100,000 in ARR was 115%. The number of paid customers with more than $100,000 in ARR jumped 44% from one year ago. Meanwhile, the company's second-largest customer, which is an unnamed international technology company, more than doubled its seat count to 60,000 from 25,000. Although Monday.com is not profitable on the basis of generally accepted accounting principles ( GAAP ), cash flow is another core profitability metric to consider. From a free cash flow perspective, the company raked in $82.4 million of free cash flow, while net cash provided by operating activities was $86.6 million in Q3. While investors may need a certain level of risk tolerance to invest in software stocks, this resilient business looks like a compelling addition to a well-diversified portfolio.
Mega Millions jackpot reaches $489M ahead of Thanksgiving: When's the next drawing?
Chase Artopoeus has two TD passes, TD run as Chattanooga tops Austin Peay 24-17 in season finale
Big Fat Quiz of The Year viewers all had the same complaint after a Strictly Come Dancing star made his debut. The annual quiz show was back tonight for another episode to mark the end of 2024. Richard Ayoade teamed up with Katherine Ryan, Chris McCausland partnered with Maisie Adam, and Judi Love teamed up with Rob Beckett. Jimmy Carr hosted the special quiz event, but fans were left puzzled by the format of the show. Strictly Come Dancing winner, Chris was on the show, but with most of the rounds involving pictures and other visual content, fans were struggling to understand how the show had made steps for Chris to take part in the programme, as Maisie had to explain the images to him. One fan wrote: " #BigFatQuizOfTheYear the questions are tough for Chris, but basically this show isn't much about questions," whilst a second added: "Chris McCausland is hardly the best booking for the #bigfatquizoftheyear when almost every round involves something visual." A third shared in response to the message on Twitter : "I'd say almost every round involving something visual is hardly the best format when one of the bookings is Chris McCausland." A fourth penned: "I love #bigfatquizoftheyear but was thinking about how they would have adapted it to make sure Chris could be involved with the picture rounds etc... the answer seems to be not at all?!?! I’m not visually impaired so rly not an authority on this but... what is going on?" as a fifth wrote: "Love seeing Chris on soo many shows atm #BigFatQuizOfTheYear ." (sic) Chris previously admitted he was "worn out" following his Strictly win. He said on Lorraine: "It’s been a really emotional Saturday night and I’m still kind of feeling worn down by it. Three and a half months rehearsing is relentless, it’s consuming. Physically and mentally it takes its toll." The comedian revealed earlier today that he was on the show. He wrote on social media: "Tonight you can catch me on #BigFatQuizOfTheYear on @Channel4 - We filmed this during the semi-final week of Strictly so I had already done eight hours of dancing before I got to enjoy this sit down, so tune in to see me looking tired but grateful for the rest." *The Big Fat Quiz of the Year is available to catch up on My4.Opinion: Trump’s Tariffs Could Be First Test of Supreme Court’s Craven MAGA Loyalty
News digest: Fico gains an ally for his trip to Moscow
President-elect Donald Trump asked the U.S. Supreme Court to pause a law that would ban the TikTok social media platform on Jan. 19 if it isn’t sold by its Chinese parent company. Trump said the court should give him time after his Jan. 20 inauguration to “pursue a political resolution” of the dispute. He didn’t take a position on the constitutionality of the disputed law, which Congress enacted on a bipartisan basis earlier this year. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Education loan provider, Credila Financial Services, previously known as HDFC Credila Financial Services Ltd, has submitted documents to the market regulator, the Securities and Exchange Board of India (SEBI) for an initial public offering (IPO) via the confidential pre-filing route. This approach enables the company to keep certain details of the draft red herring prospectus (DRHP) undisclosed to the public for the time being. In an official statement on Friday, Credila stated that it has " filed pre-draft red herring prospectus with the SEBI and stock exchanges ... in relation to the proposed initial public offering of its equity shares on the main board.” This development comes at the time of a major shift in the company's ownership structure during the financial year that ended on March 31, 2024. A private equity consortium consisting of EQT and ChrysCapital acquired a 90.01 per cent stake in Credila for Rs 9,060 crore, which included a fresh equity infusion of Rs 2,003.61 crore. Of this total, Rs 700 crore was invested in June 2023 by the previous owner, HDFC Ltd, while the remaining Rs 1,303.61 crore was contributed in March 2024 by entities from EQT and ChrysCapital. The private equity consortium, consisting of EQT and ChrysCapital, valued Credila at a pre-money valuation of Rs 10,350 crore. As of March 31, 2024, EQT holds a 72.01 per cent stake, ChrysCapital owns 18 per cent, and HDFC Bank retains a 9.99 per cent share. This change in ownership followed the Reserve Bank of India’s (RBI) directive for HDFC Bank to reduce its stake in Credila to below 10 per cent after the merger of HDFC Ltd. with HDFC Bank. For the fiscal year ending March 31, 2024, Credila experienced robust growth, with total income soaring to Rs 2,771.04 crore from Rs 1,352.18 crore in the previous year. Its profit after tax nearly doubled, rising to Rs 528.84 crore from Rs 275.92 crore. Since its founding, Credila has provided education loans to over 1.24 lakh students. Also Read: India Chooses Luxury Cars, Report Says Over 6 Vehicles Priced Over Rs 50 Lakh Get Sold Every Hour In 2024
These fast food brands don’t use ‘real eggs’ in their breakfasts, report saysNoneThe "Proud Mary" singer dealt with years of poor health before her death in 2023 Paul Natkin/Getty left an indelible mark on music and pop culture before her death at age 83. in 1939, Turner's journey from a small-town girl to one of the most successful solo artists in history was turbulent. Sharing stages with legends like the Rolling Stones, to Ike Turner and delivering chart-toppers like "Proud Mary" and "What’s Love Got to Do with It," Turner became a symbol of resilience. The singer, who would have celebrated her 85th birthday on Nov. 26, told PEOPLE in 1981 that a psychic once told her, " ." But as Tina stepped back from the stage in 2018, she started to focus on her health. In one of her final public appearances, at the premiere of the Broadway musical inspired by her life, , Turner reflected on her incredible journey. " ," she wrote in the musical's program. "I don't need another show, but I get so many cards and letters — I still can't believe how people feel about me onstage and the legacy they say I left.” Related: In her final years, Turner spent her days with her second husband, Erwin Bach, who donated a kidney to his wife in 2017. Six years later, Turner died in May 2023 at age 83. Here’s a closer look at Tina Turner's struggle with her health, her eventual death and the legacy she left behind. Dave Benett/Getty Turner died on May 24, 2023, following a long period of illness, including , an intestinal cancer diagnosis in 2016 and kidney failure, which required an organ transplant in 2017. The singer had also been diagnosed with high blood pressure in 1978. Turner's health problems were exacerbated after she suffered a stroke in 2013, three weeks after marrying her second husband, Erwin Bach, whom she had been dating for 26 years. Turner wrote in her 2018 memoir, , that she worried about potentially being paralyzed and feared that she would never dance again. Turner recovered the ability to walk but was diagnosed with intestinal cancer just three years later, in 2016. She then turned to homeopathic medicine to treat her high blood pressure after unpleasant side effects from traditional treatment, something she greatly regretted later in life, as it led to the degradation and eventual failure of her kidneys. In one of her , posted in March 2023, the star warned her fans to take their health seriously. “Show your kidneys love! They deserve it," Turner wrote. "My kidneys are victims of my not realizing that my high blood pressure should have been treated with conventional medicine.” She added, “For far too long I believed that my body was an untouchable and indestructible bastion.” In her 2018 memoir, Turner recalled feeling “ ” over her decision to forgo traditional treatment, but praised her husband Bach, writing, “He never reproached me for my mistake. Instead, he was loyal, kind and understanding - and determined to help me get through all this alive.” Bach donated a kidney to Turner in 2017, allowing her to undergo a life-saving procedure. She lived for six years following the transplant. Bertrand Rindoff Petroff/Getty Turner died at her home in Küsnacht, Switzerland, where she spent her final years with her second husband Bach. The couple moved to Switzerland in 1995. After Turner's death, a friend in the music industry told PEOPLE, "She had found true love and was able to live without fear. She had a she was around." Friend and designer Stephen Sills recalled Turner saying, “I've had a wonderful last part of life. I've enjoyed it, but I'm tired,” just two years before her passing. Walter McBride/WireImage Turner died on May 24, 2023. "The ‘Queen of Rock'n Roll’ has died peacefully today,” her publicist said at the time. “With her, the world loses a music legend and a role model.” Turner's son, just five months prior. The Grammy winner on social media, writing, “Ronnie, you left the world far too early. In sorrow I close my eyes and think of you, my beloved son." Soon after her death, remembered Turner and her portrayal of the singer in the 1993 film Bassett shared the last words Turner said to her in a tribute posted shortly after news of her death broke. “Her final words to me — for me — were, 'You never mimicked me. Instead, you reached deep into your soul, found your inner Tina, and showed her to the world.' I shall hold these words close to my heart for the rest of my days. ,” Bassett wrote on . Legendary performer and long-time friend told PEOPLE about her final visit with Turner at her Swiss home. “She was lying on the chaise and said, ‘I’m tired.’ Then for two hours we were running around the house, and she was laughing hysterically,” Cher said. “She just needed to talk and yell. . We had the best time and talked about the old times.” Getty Hollywood To You/Star Max/GC Images Turner’s death prompted an outpouring of love and recognition from those who worked with her and were inspired by her. Fans of the singer took to social media and in order to pay tribute, leaving flowers, candles and messages of remembrance and thanks. Turner’s longtime manager, Roger Davies, remembered Turner in a statement to PEOPLE. “ with her strength, incredible energy and immense talent," he wrote. "From the first day I met her in 1980 she believed in herself completely when few others did at that time." A year after Turner's death, Grammy Awards tribute to the late singer went viral. Wearing a sparkling dress and big hair as a nod to Turner’s style, Cyrus set to Turner’s hit song "Proud Mary." Getty Turner is widely considered one of the greatest performers of all time. Throughout her career, she won eight Grammys, including three Grammy Hall of Fame Awards, and five Billboard awards. She was inducted into the Rock and Roll Hall of Fame twice. With beloved songs like "River Deep Mountain," "The Best," "Proud Mary" and dozens more, her discography continues to be influential. Turner is remembered as “the Queen of Rock and Roll,” but also as a survivor of her abusive relationship with Ike Turner. She was a legendary talent in singing, dancing, stage presence and a fashion icon. The singer’s legs were almost always on display, and her love of body-bearing dance costumes ." The legendary designer and decades-long collaborator on Turner’s iconic style, Bob Mackie, remembered the singer after her death, telling PEOPLE, “It was so hard to hear that news, but at the same time, I'm not worried about her. and having a good time, I hope." Turner inspired millions with her story, through her music, her memoirs and the Broadway musical about her life, for broadcasting one of her life lessons: “You can turn poison into medicine.”
CHARLESTON, S.C. (AP) — KyKy Tandy scored 21 points and Florida Atlantic pulled away late in the second half to beat Oklahoma State 86-78 on Thursday in the Charleston Classic. It was the second straight loss by a Power Four team in the tournament after Miami fell to Drake in the opener. Florida Atlantic (4-2) plays the Bulldogs in the semifinals on Friday, while Oklahoma State (3-1) battles the Hurricanes in a consolation game. Leland Walker completed a three-point play with 4:38 left in the second half to give FAU its first lead, 68-67, since it was 16-14. Tandy made a 3-pointer from the corner to cap FAU’s 11-1 run for a 75-68 lead with 2:41 left. Oklahoma State went five-plus minutes without a field goal late in the second half until Brandon Newman made a fast-break layup with 1:17 remaining. But Ken Evans Jr. answered with a three-point play at the other end for a nine-point lead. The Cowboys turned it over on their next possession with 52.3 seconds left. Evans finished with 13 points, Walker scored 12 and Tre Carroll had 10 for FAU. The Owls attempted 49 free throws leading to three Oklahoma State players fouling out and three others finishing with four fouls. Khalil Brantley had 16 points and Robert Jennings II scored a career-high 14 points to go with 11 rebounds for Oklahoma State. Patrick Suemnick was helped off the floor with 1:40 left in the first half and did not return. Oklahoma State led 39-34 at halftime despite making just 33.3% of its shots. FAU shot a better percentage from the field (47.8) than at the free-throw line (46.7) in the first half. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketballNetanyahu says he supports proposed ceasefire with Lebanon's HezbollahTrump asks Supreme Court to delay TikTok ban so he can weigh in after he takes office
The fluoride fights are a decades-old cultural war America can’t quitGuest Opinion: Should AI be used to resurrect extinct species like the Neanderthal?
B.C. health executive fired for refusing COVID-19 vaccine loses EI appealEDMONTON - Alberta Premier Danielle Smith says the government is working to get taxpayer value for the money it paid for medication that has yet to be approved and delivered. Read this article for free: Already have an account? To continue reading, please subscribe: * EDMONTON - Alberta Premier Danielle Smith says the government is working to get taxpayer value for the money it paid for medication that has yet to be approved and delivered. Read unlimited articles for free today: Already have an account? EDMONTON – Alberta Premier Danielle Smith says the government is working to get taxpayer value for the money it paid for medication that has yet to be approved and delivered. Smith announced the plan two years ago amid a national shortage of children’s pain medication. The province spent $70 million upfront to import five million bottles from Turkey-based Atabay Pharmaceuticals. But Alberta Health Services said Friday that Health Canada only approved 1.5 million bottles or $21 million worth of product. That left a credit of $49 million. Smith said this week the holdup is with Health Canada, which would have to approve a new suite of imports for the province to get its money’s worth. “We’re waiting for Health Canada to work with AHS to identify the products, get the formulations, approve it, so that we’re able to execute on it. Those things take time,” Smith said in a year-end interview. The premier said the province had to pay the $70 million upfront. “They delivered a portion, and then the supply chains were restored, and we didn’t need to fulfil it with the two products we’d initially ordered. So we have a credit on file with Atabay,” said Smith. The government and AHS declined to say what specific products they’re seeking or when they might arrive. “We want it to be delivered soon,” said Smith. Health Canada was unable to provide an immediate response. AHS said the $70-million prepayment went to Edmonton-based medical supplier MHCare. AHS did not address questions about how common it is to pay the entire contracting fee upfront with no apparent backstops to ensure fulfilment. The costs of shipping, waste disposal and other administration tied to the deal were initially estimated to be an extra $10 million, but are yet to be finalized. NDP Leader Naheed Nenshi said Smith’s United Conservative government signed a deal that didn’t follow normal procurement practices, and it backfired. “The federal government had already signed a deal to get real Tylenol onto the shelves that arrived before the Turkish Tylenol,” he told The Canadian Press. “Albertans should be really angry, because we basically have given$80 million of taxpayers money that could have built schools.” Smith’s government has stood by the decision to import the medication because, in late 2022, parents were desperate to find relief for their children at the height of the respiratory virus season. The purchase has long been mired in difficulties. It was immediately beset by delays, as the province sought regulatory approvals and sorted out packaging and warning labels. Pharmacists had to keep some of the medicine behind the counter to make sure customers who bought it were aware of the comparatively lower dosage. Hospital neonatal units eventually stopped using it due to safety concerns. The purchase also sparked questions about whether the province’s relaxed ethics rules meant elected officials could be bought for the right price. Multiple UCP cabinet ministers have said they accepted free tickets to Edmonton Oilers hockey games during the Stanley Cup playoffs. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. They said they followed conflict-of-interest rules and denied any claims of disreputable behaviour. Health Minister Adriana LaGrange has said AHS has identified what imported adult medications it could use, is in negotiations with Atabay and is working to get approval from Health Canada. “Once those processes have been gone through, I will be happy to share exactly what those medications are,” she said Thursday. “My goal has always been to get products that we can use, get maximum value out of what’s remaining on the books there, and that’s what’s happening.” This report by The Canadian Press was first published Dec. 6, 2024. Advertisement Advertisement